NCT00544960 - A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

April 30, 2009

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

AT-101 and docetaxel

AT-101 30 mg bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops

DRUG

placebo and docetaxel

placebo 3 tabs bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops

Trial Locations (18)

Unknown

Research Site, Durham

Research Site, Arkhangelsk

Research Site, Chelyabinsk

Research Site, Kaliningrad

Research Site, Kazan'

Research Site, Moscow

Research Sites (4), Saint Petersburg

Research Site, Samara

Research Site, Stavropol

Research Site, Voronezh

Research Site, Yekaterinburg

Research Site, Dnipropetrovsk

Research Site, Donetsk

Research Site, Kharkiv

Research Site, Kyiv

Research Site, Luhansk

Research Site, Uzhhorod

Research Site, Zaporizhzhya